The role of cytokines and adhesion molecules for mobilization of peripheral blood stem cells

Stem Cells

Volumn 18, Issue 5, 2000, Pages 320-330

  Kronenwett, Ralf ^a   Martin, Simona ^a   Haas, Rainer ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Adhesion molecules; Antisense oligonucleotides; CD34+ cells; G CSF; Integrin antagonists; Mobilization; Transplantation; VLA 4

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA1 INTEGRIN; CD34 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; CYTOTOXIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HERMES ANTIGEN; HLA DR ANTIGEN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; L SELECTIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; PEPTIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 5;

ACUTE LEUKEMIA; CELL MOTILITY; COLONY FORMING UNIT GM; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PERIPHERAL BLOOD STEM CELL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0033835829     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-5-320     Document Type: Review

References (109)

1. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients
2. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF
3. + hemopoietic cells
4. Granulocyte colony-stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells
5. Primitive human hematopoietic progenitor cells express receptors for granulocyte-macrophage colony-stimulating factor
6. Expression of the G-CSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF
7. Granulocytemacrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man
8. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation
9. Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocytecolony stimulating factor
10. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting
11. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation
12. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft
13. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy
14. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells
15. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells
16. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor
17. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest
18. Sequential high-dose therapy with peripheral blood progenitor cell support in low-grade Non-Hodgkin lymphoma
19. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk breast cancer
20. + cells with a different antigenic profile post-chemotherapy compared with treatment during steady-state hematopoiesis
21. Increased serum levels of granulocyte colony-stimulation factor after autologous bone marrow or blood stem cell transplantation
22. Circulating granulocyte colony-stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation endogenous G-CSF production correlates with myeloid engraftment
23. Evidence for a novel in vivo control mechanism of granulopoiesis: Mature cell-related control of a regulatory growth factor
24. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers
25. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF
26. + hematopoietic progenitor cells during marrow recovery
27. Broad inter-individual variations in circulating progenitor cell numbers induced by granulocyte colony-stimulating factor therapy
28. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma
29. + colony-forming cell types in blood and marrow of baboons
30. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin
31. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulation factor following high-dose chemotherapy in non-Hodgkin's lymphoma
32. - cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor
33. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: Synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors
34. Hematopoietic stem cells in the blood after stem cell factor and interleukin-11 administration: Evidence for different mechanisms of mobilization
35. Rapid mobilization of hematopoietic progenitor cells in rhesus monkeys by a single intravenous injection of interleukin-8
36. BB-10010: An active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties
37. + hematopoietic progenitor cells
38. Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines
39. Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF
40. + cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation
41. + cells
42. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia
43. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells
44. Cell-dose effect in circulating stem-cell autografting
45. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma
46. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
47. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer
48. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
49. Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: Analysis of factors affecting the rate of engraftment
50. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation
51. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy
52. +) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation
53. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
54. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
55. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
56. Role of bone marrow matrix in normal and abnormal hematopoiesis
57. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of alpha4 beta1 integrin expression and function
58. Homing and mobilization in the stem cell niche
59. Expression of integrins in human bone marrow
60. Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alteration in their interaction with fibronectin
61. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells
62. Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma
63. Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells
64. Adhesion molecules in hematopoietic cells
65. + progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery
66. Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis
67. Roles for integrin very late activation antigen-4 in stroma-dependent erythropoiesis
68. A critical role of VLA-4 in erythropoiesis in vivo
69. + hemopoietic progenitor cells
70. 2/M phases of the celll cycle
71. + cells during mobilization with G-CSF
72. + haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4
73. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin
74. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice
75. Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells
76. Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway
77. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen
78. Dynamic regulation of integrins
79. Integrin signaling: The platelet paradigm
80. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity
81. Modulation of integrin activity is vital for morphogenesis
82. + and mature hematopoietic cells: An in vitro study using a human bone marrow endothelial cell line
83. Integrin affinity modulation
84. Stem cell factor modulates avidity of α4β1 and a5β1 integrins expressed on hematopoietic cell lines
85. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins
86. The effect of alpha4 beta1-integrin binding sequences of fibronectin on growth of cells from human hematopoietic progenitors
87. Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures
88. Requirement for CD44 in proliferation and homing of hematopoietic precursor cells
89. Functional activity of CD44 isoforms in haemopoiesis of the rat
90. Evidence for differences in the mechanisms by which antibodies against CD44 promote adhesion of erythroid and granulopoietic progenitors to marrow stromal cells
91. Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation
92. + progenitors to peripheral blood
93. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
94. + hematopoietic progenitor cells
95. + hematopoietic stem cells
96. + hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1
97. + cells across uncoated or fibronectin-coated filters
98. CD44v10 in hematopoiesis and stem cell mobilization
99. Blockade of late-phase airway responses and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4
100. The crystal structure of an N-terminal two-domain fragment of vascular cell adhesion molecule 1 (VCAM-1): A cyclic peptide based on the domain 1 C-D loop can inhibit VCAM-1-alpha 4 integrin interaction
101. Anti-inflammatory activity of c(ILDV-NH(CH2)5CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion
102. Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses
103. Nucleic acid therapeutics: State of the art and future prospects
104. Antisense strategies for the treatment of hematological malignancies and solid tumors
105. ICAM-1 on monocytes mediates adhesion as well as transendothelial migration and can be downregulated using antisense oligonucleotides
106. Functional analyses of antisense oligonucleotide-mediated downregulation of VLA-4 in normal and leukemic hematopoietic cells
107. Human anti-mouse antibodies
108. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man
109. Toxicological properties of several novel oligonucleotide analogs in mice